Hashimoto, Tadayoshi http://orcid.org/0000-0003-3759-1214
Nakamura, Yoshiaki
Oki, Eiji
Kobayashi, Shin
Yuda, Junichiro
Shibuki, Taro
Bando, Hideaki
Yoshino, Takayuki
Article History
Received: 28 January 2024
Accepted: 16 February 2024
First Online: 29 March 2024
Declarations
:
: Hashimoto T. has no conflict of interest. Nakamura Y. reports grants from Seagen, Inc., Genomedia, Inc., Guardant Health, Inc., Guardant Health AMEA, Inc., Tempus Labs, inc., Roche Diagnostics K.K., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd., advisory role from Guardant Health Pte Ltd., Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Exact Sciences Corporation, and Gilead Sciences, Inc. and honoraria from Guardant Health Pte Ltd., MSD K.K., Eisai Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd. Becton, Dickinson and Company, and Guardant Health Japan Corp. Oki E. reports research funding from Guardant Health, Inc. and honoraria from Chugai Pharm, Eli Lilly, Ono Pharm., Takeda Pharm., and Bristol Meyers. Kobayashi S. has no conflict of interest. Yuda J. has no conflict of interest. Shibuki T. has no conflict of interest. Bando H. reports research funding from Ono Pharmaceutical and honoraria from Ono Pharmaceutical, Eli Lilly Japan, and Taiho Pharmaceutical. Yoshino T. reports honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Merck, Bayer Yakuhin, Ono Pharmaceutical, and research funding from Amgen K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FALCO biosystems Ltd., Genomedia Inc., Molecular Health GmbH, MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Roche Diagnostics K.K., Sanofi K.K., Sysmex Corp., and Taiho Pharmaceutical Co., Ltd.